Production of Cow’s Milk Free from Beta-Casein A1 and Its Application in the Manufacturing of Specialized Foods for Early Infant Nutrition

Beta-casein (BC) is frequently expressed as BC A2 and BC A1 in cow’s milk. Gastrointestinal digestion of BC A1 results in the release of the opioid peptide beta-casomorphin 7 (BCM7) which is less likely to occur from BC A2. This work was aimed to produce milk containing BC A2 with no BC A1 (BC A2 mi...

Full description

Bibliographic Details
Main Authors: Miguel Á. Duarte-Vázquez, Carlos García-Ugalde, Laura M. Villegas-Gutiérrez, Blanca E. García-Almendárez, Jorge L. Rosado
Format: Article
Language:English
Published: MDPI AG 2017-07-01
Series:Foods
Subjects:
Online Access:https://www.mdpi.com/2304-8158/6/7/50
id doaj-d49103c69ec74f36bac343f81aa41118
record_format Article
spelling doaj-d49103c69ec74f36bac343f81aa411182020-11-25T00:38:14ZengMDPI AGFoods2304-81582017-07-01675010.3390/foods6070050foods6070050Production of Cow’s Milk Free from Beta-Casein A1 and Its Application in the Manufacturing of Specialized Foods for Early Infant NutritionMiguel Á. Duarte-Vázquez0Carlos García-Ugalde1Laura M. Villegas-Gutiérrez2Blanca E. García-Almendárez3Jorge L. Rosado4Centro de Investigación y Desarrollo Tecnológico en Enfermedades Crónicas (CINDETEC) A.C., Avenida Jurica 122, Parque Industrial Querétaro, Querétaro 76220, MexicoCentro de Investigación y Desarrollo Tecnológico en Enfermedades Crónicas (CINDETEC) A.C., Avenida Jurica 122, Parque Industrial Querétaro, Querétaro 76220, MexicoCentro de Investigación y Desarrollo Tecnológico en Enfermedades Crónicas (CINDETEC) A.C., Avenida Jurica 122, Parque Industrial Querétaro, Querétaro 76220, MexicoDIPA, Facultad de Química, Universidad Autónoma de Querétaro C.U., Cerro de las Campanas s/n, Las Campanas, Querétaro 76010, MexicoDepartamento de Investigación y Desarrollo, Nucitec, S.A. de C.V., Avenida Jurica 116, Parque Industrial Querétaro, Querétaro 76220, MexicoBeta-casein (BC) is frequently expressed as BC A2 and BC A1 in cow’s milk. Gastrointestinal digestion of BC A1 results in the release of the opioid peptide beta-casomorphin 7 (BCM7) which is less likely to occur from BC A2. This work was aimed to produce milk containing BC A2 with no BC A1 (BC A2 milk) using genetically selected CSN2 A2A2 Jersey cows. Additionally, we aimed to develop an infant formula (IF) suitable for healthy full-term infants during the first six months of life based on BC A2 milk. The concentration of BCM7 released from BC A2 IF, from commercially available IFs as well as from human milk and raw cow’s milk was evaluated after simulated gastrointestinal digestion (SGID). BC A2 IF presented the lowest mean relative abundance of BC A1 (IF 1 = 0.136 ± 0.010), compared with three commercially available IFs (IF 2 = 0.597 ± 0.020; IF 3 = 0.441 ± 0.014; IF 4 = 0.503 ± 0.011). Accordingly, SGID of whole casein fraction from BC A2 IF resulted in a significantly lower release of BCM7 (IF 1 = 0.860 ± 0.014 µg/100 mL) compared to commercially available IFs (IF 2 = 2.625 ± 0.042 µg/100 mL; IF 3 = 1.693 ± 0.012 µg/100 mL; IF 4 = 1.962 ± 0.067 µg/100 mL). Nevertheless, BCM7 levels from BC A2 IF were significantly higher than those found in SGID hydrolysates of BC A2 raw milk (0.742 ± 0.008 µg/100 mL). Interestingly, results showed that BCM7 was also present in human milk in significantly lower amounts (0.697 ± 0.007 µg/100 mL) than those observed in IF 1 and BC A2 milk. This work demonstrates that using BC A2 milk in IF formulation significantly reduces BCM7 formation during SGID. Clinical implications of BC A2 IF on early infant health and development need further investigations.https://www.mdpi.com/2304-8158/6/7/50cow’s milkinfant formulabeta-casein A2beta-casomorphin 7
collection DOAJ
language English
format Article
sources DOAJ
author Miguel Á. Duarte-Vázquez
Carlos García-Ugalde
Laura M. Villegas-Gutiérrez
Blanca E. García-Almendárez
Jorge L. Rosado
spellingShingle Miguel Á. Duarte-Vázquez
Carlos García-Ugalde
Laura M. Villegas-Gutiérrez
Blanca E. García-Almendárez
Jorge L. Rosado
Production of Cow’s Milk Free from Beta-Casein A1 and Its Application in the Manufacturing of Specialized Foods for Early Infant Nutrition
Foods
cow’s milk
infant formula
beta-casein A2
beta-casomorphin 7
author_facet Miguel Á. Duarte-Vázquez
Carlos García-Ugalde
Laura M. Villegas-Gutiérrez
Blanca E. García-Almendárez
Jorge L. Rosado
author_sort Miguel Á. Duarte-Vázquez
title Production of Cow’s Milk Free from Beta-Casein A1 and Its Application in the Manufacturing of Specialized Foods for Early Infant Nutrition
title_short Production of Cow’s Milk Free from Beta-Casein A1 and Its Application in the Manufacturing of Specialized Foods for Early Infant Nutrition
title_full Production of Cow’s Milk Free from Beta-Casein A1 and Its Application in the Manufacturing of Specialized Foods for Early Infant Nutrition
title_fullStr Production of Cow’s Milk Free from Beta-Casein A1 and Its Application in the Manufacturing of Specialized Foods for Early Infant Nutrition
title_full_unstemmed Production of Cow’s Milk Free from Beta-Casein A1 and Its Application in the Manufacturing of Specialized Foods for Early Infant Nutrition
title_sort production of cow’s milk free from beta-casein a1 and its application in the manufacturing of specialized foods for early infant nutrition
publisher MDPI AG
series Foods
issn 2304-8158
publishDate 2017-07-01
description Beta-casein (BC) is frequently expressed as BC A2 and BC A1 in cow’s milk. Gastrointestinal digestion of BC A1 results in the release of the opioid peptide beta-casomorphin 7 (BCM7) which is less likely to occur from BC A2. This work was aimed to produce milk containing BC A2 with no BC A1 (BC A2 milk) using genetically selected CSN2 A2A2 Jersey cows. Additionally, we aimed to develop an infant formula (IF) suitable for healthy full-term infants during the first six months of life based on BC A2 milk. The concentration of BCM7 released from BC A2 IF, from commercially available IFs as well as from human milk and raw cow’s milk was evaluated after simulated gastrointestinal digestion (SGID). BC A2 IF presented the lowest mean relative abundance of BC A1 (IF 1 = 0.136 ± 0.010), compared with three commercially available IFs (IF 2 = 0.597 ± 0.020; IF 3 = 0.441 ± 0.014; IF 4 = 0.503 ± 0.011). Accordingly, SGID of whole casein fraction from BC A2 IF resulted in a significantly lower release of BCM7 (IF 1 = 0.860 ± 0.014 µg/100 mL) compared to commercially available IFs (IF 2 = 2.625 ± 0.042 µg/100 mL; IF 3 = 1.693 ± 0.012 µg/100 mL; IF 4 = 1.962 ± 0.067 µg/100 mL). Nevertheless, BCM7 levels from BC A2 IF were significantly higher than those found in SGID hydrolysates of BC A2 raw milk (0.742 ± 0.008 µg/100 mL). Interestingly, results showed that BCM7 was also present in human milk in significantly lower amounts (0.697 ± 0.007 µg/100 mL) than those observed in IF 1 and BC A2 milk. This work demonstrates that using BC A2 milk in IF formulation significantly reduces BCM7 formation during SGID. Clinical implications of BC A2 IF on early infant health and development need further investigations.
topic cow’s milk
infant formula
beta-casein A2
beta-casomorphin 7
url https://www.mdpi.com/2304-8158/6/7/50
work_keys_str_mv AT migueladuartevazquez productionofcowsmilkfreefrombetacaseina1anditsapplicationinthemanufacturingofspecializedfoodsforearlyinfantnutrition
AT carlosgarciaugalde productionofcowsmilkfreefrombetacaseina1anditsapplicationinthemanufacturingofspecializedfoodsforearlyinfantnutrition
AT lauramvillegasgutierrez productionofcowsmilkfreefrombetacaseina1anditsapplicationinthemanufacturingofspecializedfoodsforearlyinfantnutrition
AT blancaegarciaalmendarez productionofcowsmilkfreefrombetacaseina1anditsapplicationinthemanufacturingofspecializedfoodsforearlyinfantnutrition
AT jorgelrosado productionofcowsmilkfreefrombetacaseina1anditsapplicationinthemanufacturingofspecializedfoodsforearlyinfantnutrition
_version_ 1725298266457767936